LA JOLLA, Calif.–(BUSINESS WIRE)—- $LBPH #DEEs–Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The PACIF
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://mmpconnect.com/longboard-pharmaceuticals-announces-positive-topline-data-from-the-pacific-study-a-phase-1b-2a-clinical-trial-for-bexicaserin-lp352-in-participants-with-developmental-and-epileptic-encephalopathie/?utm_source=rss&utm_medium=rss&utm_campaign=longboard-pharmaceuticals-announces-positive-topline-data-from-the-pacific-study-a-phase-1b-2a-clinical-trial-for-bexicaserin-lp352-in-participants-with-developmental-and-epileptic-encephalopathie
- a
- and
- announced
- Announces
- associated
- biopharmaceutical
- broad
- business
- Business Wire
- calif
- Clinical
- company
- connection
- CSS
- data
- developing
- developmental
- diseases
- evaluating
- focused
- For
- from
- highly
- http
- HTTPS
- in
- Inc.
- jpg
- LINK
- marijuana
- medical
- Medical Marijuana
- Nasdaq
- neurological
- novel
- of
- on
- oral
- Pacific
- participants
- pharmaceuticals
- phase
- plato
- Plato Data Intelligence
- PlatoData
- positive
- potentially
- Program
- range
- receptor
- selective
- Study
- The
- today
- topline
- transformative
- trial
- Wire
- with
- zephyrnet